MiR-BART18-5p was found to repress lytic replication in anti-Ig-treated Akata Burkitt’s lymphoma cell lines and in LCLs induced by TPA through its ability to target MAP3K2 [20]. This evidence concerns the gene MAP3K2 and Burkitt lymphoma.